Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,067 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Index60 Identifies Individuals at Appreciable Risk for Stage 3 Among an Autoantibody-Positive Population With Normal 2-Hour Glucose Levels: Implications for Current Staging Criteria of Type 1 Diabetes.
Nathan BM, Redondo MJ, Ismail H, Jacobsen L, Sims EK, Palmer J, Skyler J, Bocchino L, Geyer S, Sosenko JM. Nathan BM, et al. Among authors: palmer j. Diabetes Care. 2022 Feb 1;45(2):311-318. doi: 10.2337/dc21-0944. Diabetes Care. 2022. PMID: 34853027 Free PMC article.
Associations of HbA1c with the timing of C-peptide responses during the oral glucose tolerance test at the diagnosis of type 1 diabetes.
Ismail HM, Evans-Molina C, DiMeglio LA, Becker DJ, Libman I, Sims EK, Boulware D, Herold KC, Rafkin L, Skyler J, Cleves MA, Palmer J, Sosenko JM; Type 1 Diabetes Trial Net and Diabetes Prevention Trial-Type-1 (DPT-1) Study Groups. Ismail HM, et al. Among authors: palmer j. Pediatr Diabetes. 2019 Jun;20(4):408-413. doi: 10.1111/pedi.12845. Epub 2019 Apr 15. Pediatr Diabetes. 2019. PMID: 30891858 Free PMC article.
Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data.
Haller MJ, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Geyer SM, Warnock MV, Miller JL, Atkinson MA, Becker DJ, Baidal DA, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell WE, Wilson DM, Greenbaum CJ; Type 1 Diabetes TrialNet ATG-GCSF Study Group. Haller MJ, et al. Diabetes. 2019 Jun;68(6):1267-1276. doi: 10.2337/db19-0057. Epub 2019 Apr 9. Diabetes. 2019. PMID: 30967424 Free PMC article. Clinical Trial.
Early and late C-peptide responses during oral glucose tolerance testing are oppositely predictive of type 1 diabetes in autoantibody-positive individuals.
Ismail HM, Becker DJ, Libman I, Herold KC, Redondo MJ, Atkinson MA, Cleves MA, Palmer J, Sosenko J; Diabetes Prevention Trial-Type 1 (DPT-1) Study Group. Ismail HM, et al. Among authors: palmer j. Diabetes Obes Metab. 2020 Jun;22(6):997-1000. doi: 10.1111/dom.13982. Epub 2020 Feb 27. Diabetes Obes Metab. 2020. PMID: 32003110 Free PMC article.
Index60 as an additional diagnostic criterion for type 1 diabetes.
Redondo MJ, Nathan BM, Jacobsen LM, Sims E, Bocchino LE, Pugliese A, Schatz DA, Atkinson MA, Skyler J, Palmer J, Geyer S, Sosenko JM; Type 1 diabetes TrialNet Study Group. Redondo MJ, et al. Among authors: palmer j. Diabetologia. 2021 Apr;64(4):836-844. doi: 10.1007/s00125-020-05365-4. Epub 2021 Jan 26. Diabetologia. 2021. PMID: 33496819 Free PMC article.
Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts.
Voss MG, Cuthbertson DD, Cleves MM, Xu P, Evans-Molina C, Palmer JP, Redondo MJ, Steck AK, Lundgren M, Larsson H, Moore WV, Atkinson MA, Sosenko JM, Ismail HM; DPT-1 and TrialNet Study Groups. Voss MG, et al. Among authors: palmer jp. Diabetes Care. 2021 Oct;44(10):2329-2336. doi: 10.2337/dc21-0226. Epub 2021 Aug 6. Diabetes Care. 2021. PMID: 34362815 Free PMC article. Clinical Trial.
The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients.
Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC, Rafkin L, Schatz D, Eisenbarth G; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group. Sosenko JM, et al. Among authors: palmer jp. Diabetes Care. 2013 Sep;36(9):2615-20. doi: 10.2337/dc13-0425. Epub 2013 Jul 1. Diabetes Care. 2013. PMID: 23818528 Free PMC article.
Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants.
Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups. Sosenko JM, et al. Among authors: palmer jp. Diabetes. 2013 Dec;62(12):4179-83. doi: 10.2337/db13-0656. Epub 2013 Jul 17. Diabetes. 2013. PMID: 23863814 Free PMC article.
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group. Herold KC, et al. N Engl J Med. 2019 Aug 15;381(7):603-613. doi: 10.1056/NEJMoa1902226. Epub 2019 Jun 9. N Engl J Med. 2019. PMID: 31180194 Free PMC article. Clinical Trial.
5,067 results